Elsevier

Water Research

Volume 31, Issue 11, November 1997, Pages 2705-2710
Water Research

Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage

https://doi.org/10.1016/S0043-1354(97)00121-8Get rights and content

Abstract

A portion of administered pharmaceuticals are excreted unmetabolised by patients and can be found in hospital effluent and municipal sewage. Some pharmaceuticals such as anti-tumour agents are carcinogenic, mutagenic, teratogenic and fetotoxic. Little is known about their environmental impact. Therefore, the biodegradability of the widely used anti-tumour agent ifosfamide (IF) was assessed with the modified Zahn-Wellens test (OECD 302 B) and a test simulating biological sewage treatment. The biodegradation was monitored by DOC and GCMS. The concentration of IF in hospital effluent, communal sewage and the effluent from a communal sewage treatment plant (STP) was analysed as well as calculated by the amounts of water and IF used in hospitals. The expected concentration of IF in German surface waters was calculated. IF was not biodegradable in the Zahn-Wellens test and the STP simulation test. It was not adsorbed by the sewage sludge. The concentrations measured in the hospital effluents, the STP influent and the STP effluent were of the same order of magnitude as the calculated ones, indicating that no adsorption, biodegradation or other elimination of IF took place to any noticeable extent.

References (21)

  • M. Sorsa et al.

    Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals

    Mut. Res.

    (1988)
  • T. Steger-Hartmann et al.

    Trace analysis of the antineoplastics IF and cyclophosphamide in sewage water by two step solid phase extraction and GCMS

    J. Chromatogr. A

    (1996)
  • M. Allwood et al.

    The Cytotoxics Handbook

    (1993)
  • ASTA Medica AG

    Security data sheet (91/155/EWG) Ifosfamide

    (1995)
  • J. Boos et al.

    Urinary excretion of the enantiomers of IF and its inactive metabolites in children

    Cancer Chemother. Pharmacol.

    (1991)
  • DIN

    DIN 38 412 Deutsche Einheitsverfahren zur Wasser-, Abwasser- und Schlammuntersuchung

    (1996)
  • A.S. Ensslin et al.

    Biological monitoring of cyclophosphamide and IF in urine of hospital personnel occupationally exposed to cytostatic drugs

    Occup. Environ. Med.

    (1994)
  • EU

    Direction General III, Assessment of potential risks to the environment posed by medical products for human use (excluding products containing live genetically modified organisms)

    (1995)
  • V. Gilard et al.

    Determination of the urinary excretion of IF and its phosphorylated metabolites by phosphorous-31 nuclear magnetic resonance spectroscopy

    Cancer Chemother. Pharmacol.

    (1993)
  • M.P. Goren

    Determination of urinary 2 and 3-dechloroethylated metabolites of IF by high performance liquid chromatography

    J. Chromatogr—Biomed. Appl.

    (1991)
There are more references available in the full text version of this article.

Cited by (186)

View all citing articles on Scopus

Present address: Institut für Biologie II, Universität Freiburg, Schänzlestr. 1, D-79104 Freiburg i. Br., Germany.

View full text